Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.

Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.

Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) to ...

Fresh off his appointment as the head of the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), Dr George Tidmarsh has been signed in as temporary director of the ...

Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio. In June 2025, Supernus and Sage entered a definitive agreement for the acquisition, with ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.